France AI in Drug Discovery Market Size, Shares, Segments and Companies

The France AI in drug discovery market size is evaluated at USD 919.05 million in 2026 and is expected to attain around USD 5342.48 million by 2035, growing at a CAGR of 21.6% from 2026 to 2035.

Key Takeaways

• The global AI in drug discovery market size is anticipated to grow from USD 24.51 billion in 2026 to USD 160.49 billion by 2035, achieving a CAGR of 23.22%.
• North America held a major revenue share of the market by 56.94% in 2025.
• Asia-Pacific is expected to witness the fastest growth by 27.30% CAGR during the predicted timeframe.
• By type, the preclinical and clinical testing segment held a dominant position in the market in 2025.
• By type, the de novo drug design and drug optimization segment is expected to grow with the highest CAGR in the market during the studied years.
• By application, the oncology segment held the largest revenue share of the market in 2025.
• By technology, the artificial intelligence segment led the market in 2025, and is expected to expand rapidly in the market in the coming years.
• By end-user, the pharmaceutical and biotechnology companies segment accounted for the highest revenue share of the market in 2025.

Use Of AI in the Drug Discovery Industry

The primary goal of drug discovery research is to discover medicines that have a beneficial effect on the body that is, they can help prevent or treat a specific disease. Even though there are many different types of drugs, many are small chemically synthesized molecules that can specifically bind to a target molecule usually a protein involved in a disease. To find these molecules, researchers typically conduct large screens of libraries of molecules to one that has the potential to become a drug. Individuals then put this through multiple rounds of testing to a promising compound.

Further rational structure-based drug design approaches have recently become more common. These avoid the initial screening stages but still require chemists to design, synthesize, and evaluate numerous compounds to create potential new drugs. Considering that it is generally unknown which chemical structures will have both the desired biological effects and the properties needed to become an effective drug, refining a promising compound into a drug candidate can be both expensive and time-consuming. 

According to the most recent figures, the cost of bringing a new drug to market now averages US$2.6 billion. Furthermore, even if a new drug candidate looked promising in laboratory testing, it may still fail in clinical trials. Following Phase I trials, less than 10% of drug candidates reach the market. Given this, it's not surprising that experts are now looking to AI systems' unparalleled data processing potential as a way to accelerate and lower the cost of drug discovery.

Top Companies in the Market

• IBM
• Exscientia
• Insilico Medicine
• GNS Healthcare (In January 2023, the company Rebranded as Aitia)
• Google (DeepMind)
• BenevolentAI
• BioSymetrics, Inc.
• Berg Health (In January 2023, Berg Health was acquired by BPGbio Inc.)
• Atomwise Inc.
• insitro
• CYCLICA (In May 2023, CYCLICA acquired by Recursion)

Market Segments

By Type

• Preclinical and Clinical Testing
• Molecule Screening
• Target Identification
• De Novo Drug Design and Drug Optimization

By Application

• Neurology
• Infectious Disease
• Oncology
• Others

By Technology

• Machine Learning
• Other Technologies

By End-User

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Academics and Research